John Boyce

John Boyce is the current President, CEO, and Co-Founder of NanoMosaic. Prior to this, they were the President and CEO of Exosome Diagnostics from October 2015 to September 2018. John has also held positions at TigerGene LLC and NanoMosaic Inc.

John is known for their work in turning around Exosome Diagnostics and driving it to a successful acquisition by Bio-Techne within 2.5 years. John accomplished this by implementing a "3 Pillar Strategy", developing a Companion Diagnostics division and Regulatory division, and bringing in Tiger Management as an investor.

Under John's leadership, Exosome Dx became the worldwide leader in liquid biopsy deals with pharmaceutical companies within two years. The strategy that John created allowed Exosome Dx to retain any diagnostic intellectual property generated in the work.

Josh Ritchey - VP of Product Development, Qimin Quan - Co-Founder & Chief Scientific Officer, and Audrey Warner - C0-Founder & Head of Business Development report to John Boyce.